Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months
There are good reasons behind analyst's bullish views of this biotech stock.
Overview
Even with a recent pullback, Argenx (NASDAQ: ARGX) stock remains a solid winner in 2026. Its shares are up roughly 14% year-to-date, with most of the gains coming over the last three months.
Wall Street thinks that Argenx has plenty of room to run. The consensus 12-month price target for the stock indicates a potential 23% upside. Here's exactly why analysts remain bullish about this biotech stock.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.